Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kenneth C Anderson

Showing results (591-600 of 869) with videos related to

Pageof 87
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 25, 2011
Antimyeloma activity of a multitargeted kinase inhibitor, AT9283, via potent Aurora kinase and STAT3 inhibition either alone or in combination with lenalidomideLoredana Santo, Teru Hideshima, Diana Cirstea, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 2019
Correction: Resveratrol Exerts Antiproliferative Activity and Induces Apoptosis in Waldenström MacroglobulinemiaAldo M Roccaro, Xavier Leleu, Antonio Sacco, et al.
Blood|September 8, 2012
Targeting NAD+ salvage pathway induces autophagy in multiple myeloma cells via mTORC1 and extracellular signal-regulated kinase (ERK1/2) inhibitionMichele Cea, Antonia Cagnetta, Mariateresa Fulciniti, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 15, 2024
Editor's Note: A 13 mer LNA-i-miR-221 Inhibitor Restores Drug Sensitivity in Melphalan-Refractory Multiple Myeloma CellsAnnamaria Gullà, Maria Teresa Di Martino, Maria Eugenia Gallo Cantafio, et al.
Cancer Research|June 18, 2014
Selective and potent Akt inhibition triggers anti-myeloma activities and enhances fatal endoplasmic reticulum stress induced by proteasome inhibitionNaoya Mimura, Teru Hideshima, Toshiyasu Shimomura, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 30, 2003
Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implicationsConstantine S Mitsiades, Nicholas S Mitsiades, Ciaran J McMullan, et al.
Blood|April 2, 2005
SDX-101, the R-enantiomer of etodolac, induces cytotoxicity, overcomes drug resistance, and enhances the activity of dexamethasone in multiple myelomaHiroshi Yasui, Teru Hideshima, Makoto Hamasaki, et al.
Molecular Cancer Therapeutics|January 14, 2009
Janus kinase inhibitor INCB20 has antiproliferative and apoptotic effects on human myeloma cells in vitro and in vivoRenate Burger, Steven Le Gouill, Yu-Tzu Tai, et al.
The Lancet. Haematology|December 22, 2015
Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b-2 dose-escalation studyPaul G Richardson, Sundar Jagannath, Philippe Moreau, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 4, 2015
A 13 mer LNA-i-miR-221 Inhibitor Restores Drug Sensitivity in Melphalan-Refractory Multiple Myeloma CellsAnnamaria Gullà, Maria Teresa Di Martino, Maria Eugenia Gallo Cantafio, et al.
Pageof 87

Showing results (591-600 of 869) with videos related to

Sort By:
Pageof 87
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 25, 2011
Antimyeloma activity of a multitargeted kinase inhibitor, AT9283, via potent Aurora kinase and STAT3 inhibition either alone or in combination with lenalidomideLoredana Santo, Teru Hideshima, Diana Cirstea, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 2019
Correction: Resveratrol Exerts Antiproliferative Activity and Induces Apoptosis in Waldenström MacroglobulinemiaAldo M Roccaro, Xavier Leleu, Antonio Sacco, et al.
Blood|September 8, 2012
Targeting NAD+ salvage pathway induces autophagy in multiple myeloma cells via mTORC1 and extracellular signal-regulated kinase (ERK1/2) inhibitionMichele Cea, Antonia Cagnetta, Mariateresa Fulciniti, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 15, 2024
Editor's Note: A 13 mer LNA-i-miR-221 Inhibitor Restores Drug Sensitivity in Melphalan-Refractory Multiple Myeloma CellsAnnamaria Gullà, Maria Teresa Di Martino, Maria Eugenia Gallo Cantafio, et al.
Cancer Research|June 18, 2014
Selective and potent Akt inhibition triggers anti-myeloma activities and enhances fatal endoplasmic reticulum stress induced by proteasome inhibitionNaoya Mimura, Teru Hideshima, Toshiyasu Shimomura, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 30, 2003
Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implicationsConstantine S Mitsiades, Nicholas S Mitsiades, Ciaran J McMullan, et al.
Blood|April 2, 2005
SDX-101, the R-enantiomer of etodolac, induces cytotoxicity, overcomes drug resistance, and enhances the activity of dexamethasone in multiple myelomaHiroshi Yasui, Teru Hideshima, Makoto Hamasaki, et al.
Molecular Cancer Therapeutics|January 14, 2009
Janus kinase inhibitor INCB20 has antiproliferative and apoptotic effects on human myeloma cells in vitro and in vivoRenate Burger, Steven Le Gouill, Yu-Tzu Tai, et al.
The Lancet. Haematology|December 22, 2015
Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b-2 dose-escalation studyPaul G Richardson, Sundar Jagannath, Philippe Moreau, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 4, 2015
A 13 mer LNA-i-miR-221 Inhibitor Restores Drug Sensitivity in Melphalan-Refractory Multiple Myeloma CellsAnnamaria Gullà, Maria Teresa Di Martino, Maria Eugenia Gallo Cantafio, et al.
Pageof 87